Royce & Associates’s Passage Bio PASG Stock Holding History

Royce & Associates’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,200	Closed	-$1.47M	–	1034
2021 Q1	$1.47M	Buy	+4,200	New	+$1.79M	0.01%	801

Other funds holding PASG

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Royce & Associates's PASG Position: Q2 2021 in Review

Royce & Associates sold out of Passage Bio (PASG) in Q2 2021, closing a stake of 4,200 shares — an estimated $1.47M sold.

Royce & Associates first reported a position in PASG in Q1 2021 and held it in 1 quarter. The position peaked at $1.47M in Q1 2021. 102 funds tracked by Wall St. Rank hold PASG as of Q2 2021.

Royce & Associates reported no remaining Passage Bio position as of Q2 2021 after selling out during the quarter.
Royce & Associates sold 4,200 Passage Bio shares in Q2 2021, an estimated $1.47M.
Royce & Associates first reported a position in Passage Bio in Q1 2021 and held it in 1 quarter.
Royce & Associates's Passage Bio position peaked at $1.47M in Q1 2021.
102 funds tracked by Wall St. Rank held Passage Bio as of Q2 2021.

Based on Royce & Associates's 13F filing for Q2 2021, filed 6 Aug 2021.